Third Harmonic Bio Inc THRD.OQ THRD.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Third Harmonic Bio Inc is for a loss of 31 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 5.6% in the last three months.
Wall Street's median 12-month price target for Third Harmonic Bio Inc is $5.23, above its last closing price of $5.15.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.28 | -0.34 | -0.48 | Missed | -41.2 |
Sep. 30 2024 | -0.30 | -0.30 | -0.33 | Missed | -10.4 |
Jun. 30 2024 | -0.24 | -0.27 | -0.26 | Beat | 3.7 |
Mar. 31 2024 | -0.30 | -0.31 | -0.20 | Beat | 35.3 |
Dec. 31 2023 | -0.31 | -0.17 | Beat | 45.2 | |
Sep. 30 2023 | -0.27 | -0.27 | -0.19 | Beat | 29.6 |
Jun. 30 2023 | -0.30 | -0.30 | -0.19 | Beat | 36.7 |
Mar. 31 2023 | -0.35 | -0.35 | -0.40 | Missed | -14.3 |
This summary was machine generated May 9 at 16:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)